Review Article
The Use of Multiple Primary Outcomes in Randomized Controlled Trials of Chinese Herbal Medicine
Table 1
Summary of the characteristics of included RCTs.
| | Variable | | Number of RCTs (n = 227) | Variable | | Number of RCTs (n = 227) |
| | Year | 2010 | 18 (7.9%) | Country | Mainland China | 197 (86.8%) | | 2011 | 20 (8.8%) | Hong Kong | 11 (4.8%) | | 2012 | 22 (9.7%) | Taiwan | 8 (3.5%) | | 2013 | 31 (13.6%) | Singapore | 2 (0.9%) | | 2014 | 19 (8.4%) | America | 2 (0.9%) | | 2015 | 28 (12.3%) | Australia | 2 (0.9%) | | 2016 | 18 (7.9%) | Brazil | 1 (0.4%) | | 2017 | 21 (9.2%) | India | 1 (0.4%) | | 2018 | 25 (11.0%) | Iran | 1 (0.4%) | | 2019 | 25 (11.0%) | Netherlands | 1 (0.4%) |
| | Arms per trial | 2 | 193 (85.0%) | Sample size | Korea | 1 (0.4%) | | 3 | 28 (12.3%) | Range | 12–3,143 | | 6 | 6 (2.6%) | Median (IQR) | 115 (72–228) |
|
|
